NASDAQ · BBIO
BridgeBio Pharma, Inc.
$70.73-$0.09 (-0.13%)
BridgeBio Pharma, Inc.’s quoted price sits in the lower half of its reported 52-week range, 24.29% below the high.
Loading market information…
NASDAQ · PTCT · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
PTC Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 29.06% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
PTC Therapeutics, Inc.’s next earnings report is currently expected on Feb 18, 2027, with estimated earnings per share of $0.27. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow PTC Therapeutics, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
PTC Therapeutics, Inc. (PTCT) is a biopharmaceutical company committed to the research, development, and commercialization of innovative therapies for patients afflicted with rare genetic disorders. Its robust pipeline encompasses both commercialized therapies and a variety of experimental drug candidates, spanning all stages of development—from early research and preclinical studies to clinical trials—with a primary focus on addressing various rare disease indications. Among its commercialized products, PTC Therapeutics provides Translarna and Emflaza, offering therapeutic options for Duchenne muscular dystrophy patients in the European Economic Area and the United States. Translarna also addresses nonsense mutation Duchenne muscular dystrophy in Brazil and Russia. The company additionally commercializes Tegsedi and Waylivra for various rare conditions throughout Latin America and the Caribbean. Furthermore, in Brazil, PTC Therapeutics distributes Evrysdi as a treatment for spinal muscular atrophy (SMA) in patients aged two months and older. Leveraging its proprietary splicing platform, the company is also actively developing PTC518, a promising therapeutic candidate aimed at treating Huntington's disease. To bolster its research and development capabilities, PTC Therapeutics has established strategic collaborations, including partnerships with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc., as well as the Spinal Muscular Atrophy Foundation, focusing on advancing drug discovery and development research, particularly in regenerative medicine. Additionally, it collaborates with Akcea Therapeutics, Inc. for the commercialization of Tegsedi and Waylivra in the Latin America and Caribbean region. Established in 1998, PTC Therapeutics, Inc. maintains its corporate headquarters in South Plainfield, New Jersey.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 03:09 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q2 2025 | Aug 7, 2025 | -$0.83+22.43% vs estimate | $178.88M-6.57% vs estimate |
|---|
| Q1 2025 | May 6, 2025 | $10.04+1,029.63% vs estimate | $1.18B+215.64% vs estimate |
|---|
| Q4 2024 | Feb 27, 2025 | -$0.85+24.11% vs estimate | $213.17M-8.29% vs estimate |
|---|
THE ANALYST VIEW
26 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Consensus coverage: 9 contributors · Median target $104.00.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$70.73-$0.09 (-0.13%)
BridgeBio Pharma, Inc.’s quoted price sits in the lower half of its reported 52-week range, 24.29% below the high.
$57.49+$1.49 (+2.66%)
BioMarin Pharmaceutical Inc.’s quoted price sits in the lower half of its reported 52-week range, 19.01% below the high.
$324.55+$3.13 (+0.97%)
Krystal Biotech, Inc.’s quoted price sits in the upper half of its reported 52-week range, 15.16% below the high.
$44.39-$0.51 (-1.14%)
Ionis Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 48.82% below the high.
$17.04+$0.06 (+0.35%)
Dyne Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 37.61% below the high.
$19.23-$0.09 (-0.47%)
Sarepta Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 56.43% below the high.
$16.78-$0.42 (-2.44%)
Ultragenyx Pharmaceutical Inc.’s quoted price sits in the lower half of its reported 52-week range, 57.93% below the high.
$3.63-$0.01 (-0.27%)
Wave Life Sciences Ltd.’s quoted price sits in the lower half of its reported 52-week range, 83.29% below the high.
